Cell Membrane-bound TLR2 and TLR4: Potential Predictors of Active Systemic Lupus Erythematosus and Lupus Nephritis

MARÍA PÉREZ-FERRO, CRISTINA SERRANO DEL CASTILLO and OLGA SÁNCHEZ-PERNAUTE

J Rheumatol 2016;43;1444-1445
http://www.jrheum.org/content/43/7/1444

1. Sign up for TOCs and other alerts
http://www.jrheum.org/alerts

2. Information on Subscriptions
http://jrheum.com/faq

3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Cell Membrane-bound TLR2 and TLR4: Potential Predictors of Active Systemic Lupus Erythematosus and Lupus Nephritis

To the Editor:

Innate immune receptors have been found to be involved in the pathogenesis of systemic lupus erythematosus (SLE)\(^1\). The binding of nucleic acids to the endosomal Toll-like receptors (TLR) 7 and TLR9 is considered as a triggering mechanism for the production of antinuclear antibodies\(^2,3\). Also, the cell membrane-bound TLR (mbTLR) might contribute to enhance immune cell responses in SLE. Besides detecting microorganisms, these receptors engage molecules exposed upon apoptosis, such as the DNA-binding high mobility group protein B1, which is thought to facilitate self-DNA antigenicity\(^4\). The contribution of the mbTLR TLR2 and TLR4 to loss of tolerance and development of nephritis has been consistently found in SLE models conducted in transgenic mice\(^5,6,7\). However, there is little information about the activation of mbTLR during SLE flares in humans.

We have studied TLR2 and TLR4 protein levels in peripheral blood mononuclear cells from patients with SLE (n = 35) and healthy controls (n = 11) using flow cytometry. Patients were receiving stable medication at the time of the study, and had no signs of active infection. Whereas no global differences in the levels of the mbTLR were noted between the cohorts, the density of TLR4 was significantly increased in the B cells of patients with active (n = 20) compared to inactive (n = 15) SLE (Figure 1A). Levels of TLR4 in these cells were correlated with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the British Isles Lupus Assessment Group index (BILAG) activity scores (Figure 1B) and also with the erythrocyte sedimentation rate (p < 0.001, not shown). Similarly, the amounts of both mbTLR in T cells and that of TLR4 in monocytes were found to increase in parallel with activity measures (not shown). There was no association between the expression of any of these molecules and anti-DNA antibody titers or complement levels. Dose of corticosteroids was neither related to the ones acknowledged, which could show up in particular subgroups of patients with SLE. It is tempting to suggest a relationship with the expression of mbTLR in circulating mononuclear cells from patients with SLE might be useful as an additional marker of disease activity\(^8\). Interestingly, we further observed that the enhancement of the mbTLR was associated to concurrent active nephritis (aLN). As compared with the rest of the cohort, patients with aLN had higher levels of TLR4 in B cells and monocytes and higher levels of TLR2 in lymphocytes (Figure 2A). In addition, urinary protein excretion rates were associated to both the expression of TLR2 in T lymphocytes and of TLR4 in monocytes (Figure 2B).

Although based on few patients, our data point to a possible involvement of TLR2 and TLR4 in the activation of mononuclear cells during SLE flares and nephritis. Our results are in agreement with a previous study conducted in 16 women with SLE, in whom an association was found between the expression of T lymphocyte TLR4 levels and disease activity\(^9\). Interestingly, neither study found any association between anti-DNA antibody titers and the expression of mbTLR in mononuclear cells. This fact may indicate that the enhancement of these molecules translates a different activation pathway to the ones acknowledged, which could show up in particular subgroups of patients with SLE. It is tempting to suggest a relationship with the involvement of infections in SLE flares. Mechanistically, pathogens could enhance mbTLR activity and cause tissue injury. Thereby, cooperation of mbTLR with endosomal TLR might boost the reactivity of the latter toward autoantigens. In this line of thought, data have shown the participation of TLR2 and TLR4 in the recognition and internalization of heparosan\(^10\), a family of pathogens closely associated to the disease. Also possible is that the upregulation of mbTLR could be a consequence of the acute-phase response, as elegantly shown in a model of lupus nephritis in which tissue damage is elicited by a cytokine-dependent upregulation of TLR2 and TLR4 in local endothelial cells\(^11\).

Altogether, the results drawn in mice and our current findings suggest that mbTLR could be particularly involved in nephritis. There is an increasing body of evidence that activation of mbTLR also underlies other types of immune-mediated nephritis in humans. As an example, a study showed an enhancement of TLR4 in mononuclear cells from children with Henoch-Schönlein purpura and high-grade proteinuria\(^12\).

Our data suggest that the detection of TLR2 and TLR4 in circulating mononuclear cells from patients with SLE might be useful as an additional marker of disease activity, and in particular of active nephritis. Replication of these results in other cohorts is warranted to confirm their relevance.

MARÍA PÉREZ-FERRO, MD, Division of Rheumatology, Jiménez Díaz Foundation Health Research Institute and University Hospital; CRISTINA SERRANO DEL CASTILLO, MD, Division of Immunology, Jiménez Díaz Foundation Health Research Institute and University Hospital; OLGA SÁNCHEZ-PERNAUTE, MD, PhD, Division of Rheumatology, Jiménez Díaz Foundation Health Research Institute and University Hospital, Madrid, Spain. Supported by a grant from the Spanish Ministry for Health, nonoriented research program, Fondo de Investigación de la Seguridad Social (FIS-F101000337); Address correspondence to Dr. O. Sánchez-Pernaute, Division of Rheumatology, Jiménez Díaz Foundation Health Research Institute and University Hospital, Avda. Reyes Católicos 2, 28040 Madrid, Spain. E-mail: osanchez@fjd.es

*Correspondence: osanchez@fjd.es

**Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.

Downloaded from www.jrheum.org on November 6, 2017 - Published by The Journal of Rheumatology
REFERENCES


J Rheumatol 2016;43:7; doi:10.3899/jrheum.151386